Status:
COMPLETED
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
50+ years
Phase:
PHASE3
Brief Summary
To compare recurrence free survival between two treatment groups (5 years with exemestane vs 2.5 to 3 years tamoxifen followed by 2 to 2.5 years of exemestane for a total duration of 5 years) This Pf...
Eligibility Criteria
Inclusion
- HR+ post-menopausal patients with non-metastatic breast cancer
Exclusion
- Any of the following: HR-, non-menopausal patient, metastatic breast cancer
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
9779 Patients enrolled
Trial Details
Trial ID
NCT00279448
Start Date
January 1 2002
End Date
June 1 2009
Last Update
December 23 2011
Active Locations (59)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Marseille, Be1 01971, France, 13285
2
Pfizer Investigational Site
Compiègne, Be1 02256, France, 60200
3
Pfizer Investigational Site
Rennes, Be1 03677, France, 35033
4
Pfizer Investigational Site
Brest, Be1 04292, France, 29609